Posted on

Microdoses for the whole family

Mindset Pharma Announces Filing of International Patent Application Covering its Family 3 “Microdose” Compounds

Here’s a fun way to bond with grandma…

Mindset Pharma (MSET) filed a patent for psilocybin microdoses that have potential to treat Alzheimer’s disease and ADHD. 

The compounds may promote cognitive benefits without the liability of a psychedelic experience, making them suitable for “fragile population groups” like children and the elderly, according to the company’s Chief Scientific Officer.

PDF of article

Posted on

Make your New Year’s resolutions stick

Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder To Include Additional Behavioral Addictions

Spent too much time gaming or had too much sex in 2021? 

We’re guessing you didn’t answer yes to both, but if you struggle with one of these things, ketamine therapy could help you make changes this year 😉

Awakn Life Sciences (AWKN) received ethics approval to expand its ketamine study. In addition to investigating Gambling Disorder, it will now cover three more behavioral addictions: Internet Gaming Disorder, Compulsive Sexual Behaviour, and Binge Eating Disorder.

The goal is to “harness a window in which the brain is able to make new connections” to create lasting behaviour changes. 

PDF of article

logo